Pfizer Biosimilars...potentially expanding patient, provider, and payer options

Biosimilars provide the potential to offer a broader range of treatment options. As potential alternatives to originator biologics, biosimilars may improve access and provide cost savings to health care. Pfizer, one of the world's premier innovative biopharmaceutical companies, is committed to bringing high-quality biosimilars to patients, providers, and payers, with nearly 10 years of experience with biosimilars, 3 marketed biosimilars outside the United States, and 4 biosimilars in late-stage clinical development.